The analysis of clinical trials revealed an urgent need to increase the development of Alzheimer drugs

The analysis of clinical trials revealed an urgent need to increase the development of Alzheimer drugs -

The analysis of clinical trials shows pipeline therapeutics is low; 99.6 percent of attempts fail drug

Researchers at the Lou Ruvo Cleveland Clinic Center for Brain Health conducted the first analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase the number of agents within the drug development pipeline AD and move successfully into new treatment therapy. The document, "Disease Drug Development Pipeline Alzheimer: Few candidates, frequent failures", was published today in the journal Alzheimer's Research & Therapy

An overview all clinical trials shows .:

• There are relatively few drugs in development for Alzheimer's disease.
• the failure rate for developing AD drugs was 99.6 percent for the decade 02-2012.
• the number of drugs has decreased since 09.

"Our goal was examine historical trends to help understand why the treatment of the disease of Alzheimer's development efforts fail so often, "said Jeffrey L. Cummings, MD, D.Sc., Director of the Centre Lou Ruvo Cleveland Clinic for brain health. "with approximately 44 million people worldwide with the condition, the study shows that the drug development ecosystem disease of Alzheimer's disease need more support given the magnitude of the problem. "

By using the advanced search mechanisms ClinicalTrials.gov, a government website which records all clinical trials, Dr. Cummings and Kate Zhong, MD, senior director of research and development clinical and Touro University medical student Travis Morstorf built a comprehensive analysis to examine all tests since 02.

"by analyzing both completed and ongoing trials and is currently active compounds, we been able to provide an overview of longitudinal trends in drug development, "said Dr. Zhong. "We found that investment in AD therapies and drugs is relatively low compared to the challenge posed by the disease. The pipeline is almost dry."

This comprehensive analysis illustrates the high failure rate of compounds and the need for a constant supply of new drugs or a higher emphasis on reorientation, which can be evaluated for efficacy in AD. With AD more to the US economy as cardiovascular disease or cancer, Lou Ruvo Center for Brain Health Research team believes the AD drug system must be supported, cultivated and coordinated to improve the rate and successful development of new therapies.

to accelerate the drug development process and reduce the need to constantly invent new drugs, researchers note the need for other repositioning studies, which involve the study of a approved drug in a new or used condition. For example, researchers at the Cleveland Clinic Centre Lou Ruvo Brain Health for conducting a Phase IIa clinical trial of a benchmark to determine whether bexarotene (Targretin-), a currently FDA-approved drug to treat the cancer skin, can remove an accumulation of proteins in the brains of Alzheimer's patients, as he did in a recent animal study.